SOURCE: BioMedReports

BioMedReports

June 21, 2011 07:01 ET

Senesco's Shares Primed After Positive Regulatory News Development

LOS ANGELES, CA--(Marketwire - Jun 21, 2011) - Senesco Technologies (NYSE Amex: SNT) announced after-hours on Monday that the Company had been informed by U.S. regulators that all clinical hold issues on Senesco's Investigational New Drug application for their lead product candidate SNS01-T had been lifted.

SNS01-T has been developed for the treatment of multiple myeloma, an incurable blood cancer that causes an accumulation of cancerous plasma cells (a type of B cell normally responsible for antibody production) in the bone marrow, which leads to destruction of the bone and interference with the normal production of immune system cells.

This positive response from the FDA granting SNT an open IND should generate investor interest in the company and a special report about what this development could mean for investors is available now at:

http://biomedreports.com/2011062169136/senescos-positive-news-may-send-shares-higher.html

In addition, investors interested in making more profitable trades can access BioMedReports' new Complete Database of Clinical Trials and Upcoming FDA and World-Wide Regulatory Decisions as well as our trade alerts (like the one issued for Senesco on Monday) at:

http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556